Earnings call transcript: BioArctic Q2 2026 revenue growth offsets softer profit

BioArctic reported Q2 2026 net revenues of SEK 248M (flat YoY) as operating profit remained slightly negative, but the revenue mix improved: Leqembi royalties rose to SEK 179.4M (+12% sequentially, +27% YoY) and recurring revenues are nearing SEK 200M/quarter. Shares fell 4.64% to $329 pre-market, with investors likely focused on the lack of a clear earnings re-rate and the still-loss-making quarter despite cash of ~SEK 2.0B (rising to >SEK 2.3B after Eli Lilly’s $30M upfront). The company reaffirmed full-year 2026 profitability despite operating costs rising 40%-60%, supported by FDA approval of the subcutaneous Iqlik initiation in the U.S. and additional launch/approval catalysts in Japan and China.

Analysis

BioArctic is transitioning from milestone-driven noise to a royalty annuity, which matters more than the modest headline print. The main winners are BioArctic and Eisai: the former gets cleaner cash flow and platform validation, the latter gets the commercial upside from easier administration. The loser is the bear case that this is still just a one-product story; the cash balance and partner-led funding reduce near-term financing risk, so the market is more likely to re-rate on adoption data than on earnings optics.

The second-order issue is timing. The U.S. subcutaneous launch is an immediate narrative catalyst, but the real P&L inflection likely sits 1-3 quarters out, once coverage expands and prescribing friction falls. If uptake is slow, the stock can de-rate quickly because the multiple already prices in success; if uptake is faster than expected, the operating leverage from high-margin royalties can surprise to the upside without requiring a full pipeline readout.

Contrarian view: consensus may be too focused on the new formulation as an instant revenue step-change. In reality, reimbursement, site-of-care economics, and physician switching inertia make this a gradual adoption curve, especially outside the U.S. The bigger medium-term swing factor is whether the platform validation from Lilly converts into additional partnered programs; that is the path to justify the premium multiple beyond Leqembi. Falsifiers: no visible step-up in quarterly royalties by Q4, or any delay in Japan/China coverage that pushes the growth curve into 2027.

Key Decisions for Investors

• Buy BRCTF on weakness for a 1-3 month trade, targeting the next catalyst window into CTAD and Japan reimbursement; risk/reward improves if the stock stays below the recent post-earnings level despite no deterioration in royalty guidance.
• If building a longer-dated position, use BRCTF call spreads into late 2026 rather than stock, since the upside case depends on adoption acceleration and additional partner validation, while near-term multiple compression is a real risk.
• Avoid chasing ESAIY here; it is the cleaner commercial beneficiary, but BioArctic has the better leverage to recurring royalties plus platform optionality. Use ESAIY only if you want direct exposure to launch execution rather than royalty compounding.
• Pair trade: long BRCTF / short XBI as a quality-biotech hedge. The thesis is that royalty-backed, partner-funded biotech should outperform cash-burning CNS names if rates stay restrictive and risk appetite fades; stop out if biotech financing conditions improve broadly.
• Set a hard watch item on Q3/Q4: if recurring revenue does not visibly accelerate after the U.S. subcutaneous launch, fade the multiple and trim longs; if it does, add on confirmation rather than anticipation.